Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920

摘要

Skelin et al. (1) have raised an important issue about competing risk in time-to-event analyses of acute gallbladder or biliary disease in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (2). We thank them for the opportunity to discuss the data in the light of competing risk from a lower frequency of all-cause death with liraglutide compared with placebo in LEADER (3).